CCA
EDIT icon

Column Capital Advisors’s Editas Medicine EDIT Stock Holding History

Column Capital Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-56
Closed -$1K – 741
2019
Q4 		$1K Buy
+56
New +$1.4K ﹤0.01% 649

Other funds holding EDIT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Column Capital Advisors's EDIT Position: Q1 2020 in Review

Column Capital Advisors sold out of Editas Medicine (EDIT) in Q1 2020, closing a stake of 56 shares — an estimated $1K sold.

Column Capital Advisors first reported a position in EDIT in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 199 funds tracked by Wall St. Rank hold EDIT as of Q1 2020.

  • Column Capital Advisors reported no remaining Editas Medicine position as of Q1 2020 after selling out during the quarter.
  • Column Capital Advisors sold 56 Editas Medicine shares in Q1 2020, an estimated $1K.
  • Column Capital Advisors first reported a position in Editas Medicine in Q4 2019 and held it in 1 quarter.
  • Column Capital Advisors's Editas Medicine position peaked at $1K in Q4 2019.
  • 199 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.